Cargando…
Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients
BACKGROUND: Multitargeted tyrosine kinase inhibitors (TKIs) represent a new class of target-specific antineoplastic agents. These agents show some specific adverse events such as fatigue/asthenia, anorexia/loss of appetite, dysgeusia, diarrhea/abdominal pain, hypothyroidism, hypertension, myelosuppr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994328/ https://www.ncbi.nlm.nih.gov/pubmed/29992147 http://dx.doi.org/10.1155/2018/5035217 |
_version_ | 1783330425603620864 |
---|---|
author | Arena, Claudia Troiano, Giuseppe De Lillo, Alfredo Testa, Nunzio F. Lo Muzio, Lorenzo |
author_facet | Arena, Claudia Troiano, Giuseppe De Lillo, Alfredo Testa, Nunzio F. Lo Muzio, Lorenzo |
author_sort | Arena, Claudia |
collection | PubMed |
description | BACKGROUND: Multitargeted tyrosine kinase inhibitors (TKIs) represent a new class of target-specific antineoplastic agents. These agents show some specific adverse events such as fatigue/asthenia, anorexia/loss of appetite, dysgeusia, diarrhea/abdominal pain, hypothyroidism, hypertension, myelosuppression, and stomatitis. MATERIALS AND METHODS: A systematic search was performed on PubMed online database using a combination of MESH terms and free text words, “sunitinib” OR “sorafenib” OR “axitinib” OR “cabozantinib” OR “pazopanib” OR “regorafenib” OR “nintedanib” OR “vatalanib” combined through the use of Boolean operator AND with the key words “stomatitis” OR “mucositis,” (i) on human subjects, (ii) written in the English language, and (iii) reporting about the incidence of stomatitis or oral mucositis. RESULTS: The incidence of stomatitis of any grade was 35.2% for sunitinib, 20.52% for sorafenib, 20.63% for axitinib, and 34.21% for cabozantinib. All the agents showed high rates of low-grade stomatitis (G1-G2), while the onset of severe stomatitis (G3-G4) was very low. CONCLUSIONS: Analysis of the reports with patients treated with sunitinib, sorafenib, axitinib, and cabozantinib showed a clear prevalence of stomatitis grade 1 or grade 2. These data differ from those of patients treated with conventional chemotherapy in which mucositis is predominantly of grade 3 or grade 4. |
format | Online Article Text |
id | pubmed-5994328 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-59943282018-07-10 Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients Arena, Claudia Troiano, Giuseppe De Lillo, Alfredo Testa, Nunzio F. Lo Muzio, Lorenzo Biomed Res Int Review Article BACKGROUND: Multitargeted tyrosine kinase inhibitors (TKIs) represent a new class of target-specific antineoplastic agents. These agents show some specific adverse events such as fatigue/asthenia, anorexia/loss of appetite, dysgeusia, diarrhea/abdominal pain, hypothyroidism, hypertension, myelosuppression, and stomatitis. MATERIALS AND METHODS: A systematic search was performed on PubMed online database using a combination of MESH terms and free text words, “sunitinib” OR “sorafenib” OR “axitinib” OR “cabozantinib” OR “pazopanib” OR “regorafenib” OR “nintedanib” OR “vatalanib” combined through the use of Boolean operator AND with the key words “stomatitis” OR “mucositis,” (i) on human subjects, (ii) written in the English language, and (iii) reporting about the incidence of stomatitis or oral mucositis. RESULTS: The incidence of stomatitis of any grade was 35.2% for sunitinib, 20.52% for sorafenib, 20.63% for axitinib, and 34.21% for cabozantinib. All the agents showed high rates of low-grade stomatitis (G1-G2), while the onset of severe stomatitis (G3-G4) was very low. CONCLUSIONS: Analysis of the reports with patients treated with sunitinib, sorafenib, axitinib, and cabozantinib showed a clear prevalence of stomatitis grade 1 or grade 2. These data differ from those of patients treated with conventional chemotherapy in which mucositis is predominantly of grade 3 or grade 4. Hindawi 2018-05-24 /pmc/articles/PMC5994328/ /pubmed/29992147 http://dx.doi.org/10.1155/2018/5035217 Text en Copyright © 2018 Claudia Arena et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Arena, Claudia Troiano, Giuseppe De Lillo, Alfredo Testa, Nunzio F. Lo Muzio, Lorenzo Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients |
title | Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients |
title_full | Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients |
title_fullStr | Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients |
title_full_unstemmed | Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients |
title_short | Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients |
title_sort | stomatitis and vegfr-tyrosine kinase inhibitors (vr-tkis): a review of current literature in 4369 patients |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994328/ https://www.ncbi.nlm.nih.gov/pubmed/29992147 http://dx.doi.org/10.1155/2018/5035217 |
work_keys_str_mv | AT arenaclaudia stomatitisandvegfrtyrosinekinaseinhibitorsvrtkisareviewofcurrentliteraturein4369patients AT troianogiuseppe stomatitisandvegfrtyrosinekinaseinhibitorsvrtkisareviewofcurrentliteraturein4369patients AT delilloalfredo stomatitisandvegfrtyrosinekinaseinhibitorsvrtkisareviewofcurrentliteraturein4369patients AT testanunziof stomatitisandvegfrtyrosinekinaseinhibitorsvrtkisareviewofcurrentliteraturein4369patients AT lomuziolorenzo stomatitisandvegfrtyrosinekinaseinhibitorsvrtkisareviewofcurrentliteraturein4369patients |